OXURION Confirms Institutional Review Board Approval and Sub

OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)

OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

, Euronext Brussels , Retinal Disorders , Diabetic Macular Edema , Dime , Iopharmaceutical Company , Rscva , Phase 2 Clinical Trial , Intravitreal Injection , Investigational New Drug , Vascular Disorders , Food And Drug Administration , என்னை , சிவ ,